1. Home
  2. |Insights
  3. |Did I Hear That Correctly? DOJ Antitrust Division Seeks to Criminally Prosecute Monopolization

Did I Hear That Correctly? DOJ Antitrust Division Seeks to Criminally Prosecute Monopolization

Client Alert | 1 min read | 03.04.22

This week, a DOJ Antitrust Division official signaled a significant expansion of its criminal enforcement program. While speaking at the ABA White Collar Conference in San Francisco, Deputy Assistant Attorney General Richard Powers said that the Division is considering criminally prosecuting violations of Section 2 of the Sherman Act, which prohibits monopolization. This is a major break from long-standing Division policy that it would prosecute only per se violations of the antitrust laws, and raises potentially significant due process concerns.

Although the Division has not brought criminal charges for a Section 2 violation in over 40 years, Powers explained that the Division historically did not shy from bringing criminal monopolization cases and will use “all available tools” to enhance antitrust enforcement. Powers gave no guidance about the circumstances in which the Division would consider such charges, other than to say that if the facts and law led the Division to believe criminal charges were warranted, they would bring a case.

Without further guidance from the Division, companies will have to fall back on foundational antitrust principles and ensure employees are adequately trained and business practices comply with current laws. Although the Division may be on the hunt for criminal cases, the legal strictures of the Sherman Act remain unchanged. Criminal enforcement of claims of monopolization or attempted monopolization, which are by definition subject to a Rule of Reason balancing test (not a per se prohibition), would have to overcome years of precedent limiting criminal violations to naked restraints of trade, and raises potentially significant concerns regarding due process, notice, and lenity.

Powers’ statements are consistent with other recent moves by the Division to expand criminal enforcement of the antitrust laws. In particular, the Division’s move to criminally prosecute “no-poach” agreements is another example of conduct that was historically subject to civil enforcement that the Division has sought to criminalize over the last several years. Beginning in 2016, the Division announced it considered naked no-poach agreements a per se violation of the antitrust laws subject to criminal enforcement. In 2020, the Division brought its first criminal charges for no-poach agreements, and it remains a significant enforcement priority.

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...